GlassScriptPhysician profile
Javier Narvarte
NPI 1326156134
$6,218.43
in general payments reported to CMS, 2019-2025
45 companies · $896 in 2025
The $896 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $604 · 2020: $335 · 2021: $512 · 2022: $479 · 2023: $426 · 2024: $2,966 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,275 · Travel and Lodging: $1,960 · Education: $53.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,275.12 |
| Travel and Lodging | $1,959.51 |
| Education | $53.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $2,138.26 | 2024 | |
| Amgen INC. | $519.53 | 2019-2025 | Krystexxa, Tavneos, Aranesp |
| Calliditas Therapeutics US INC. | $390.76 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $340.23 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $310.56 | 2019-2024 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $242.64 | 2019-2025 | Lokelma, Farxiga |
| Glaxosmithkline, LLC. | $230.88 | 2020-2025 | Benlysta |
| Opko Pharmaceuticals, LLC | $197.49 | 2019-2025 | Rayaldee |
| Travere Therapeutics, INC. | $182.38 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $179.14 | 2024-2025 | |
| Vifor Pharma, INC. | $112.51 | 2020-2023 | Veltassa |
| Apellis Pharmaceuticals, INC. | $104.87 | 2025 | |
| Aurinia Pharma U.S., INC. | $102.54 | 2022-2025 | Lupkynis |
| Akebia Therapeutics INC | $88.76 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $86.18 | 2021-2023 | Acthar |
Show all 44 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Narvarte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.